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Background: Unique adhesive and biocompatibility properties of mussel adhesive proteins (MAPs) are known for their
great potential in many tissue engineering and biomedical applications. Previously, it was successfully demonstrated that
redesigned hybrid type MAP, fp-151, mass-produced in Gram-negative bacterium Escherichia coli, could be utilized as a
promising adhesive biomaterial. However, purification of recombinant fp-151 has been unsatisfactory due to its adhesive
nature and polarity which make separation of contaminants (especially, lipopolysaccharide, a toxic Gram-negative cell
membrane component) very difficult.
Results: In the present work, we devised a high resolution purification approach to secure safety standards of
recombinant fp-151 for the successful use in in vivo applications. Undesirable impurities were remarkably eliminated as
going through sequential steps including treatment with multivalent ion and chelating agent for cell membrane washing,
mechanical cell disruption, non-ionic surfactant treatment for isolated inclusion body washing, acid extraction of washed
inclusion body, and ion exchange chromatography purification of acid extracted sample. Through various analyses, such
as high performance liquid chromatographic purity assay, limulus amoebocyte lysate endotoxin assay, and in vitro mouse
macrophage cell tests on inflammation, viability, cytotoxicity, and apoptosis, we confirmed the biological safety of
bacterial-derived purified recombinant fp-151.
Conclusions: Through this purification design, recombinant fp-151 achieved 99.90% protein purity and 99.91%
endotoxin reduction that nearly no inflammation response was observed in in vitro experiments. Thus, the highly
purified recombinant MAP would be successfully used as a safety-secured in vivo bioadhesive for tissue engineering
and biomedical applications.
Keywords: Mussel adhesive protein, Gram-negative Escherichia coli, High resolution purification, Biosafety,
Lipopolysaccharide, Endotoxin, In vivo standardBackground
Mussels use unique protein-based bioadhesives that can
maintain strong adhesiveness even in the aquatic environ-
ment to survive in the ocean [1,2]. Mussel adhesive proteins
(MAPs) are also known for displaying excellent biocompati-
bility and biodegradability [3-5]. These unique properties
make MAPs promising and valuable biomaterials that can
be utilized in different tissue engineering and medical appli-
cations [6,7]. Since extracting natural adhesive proteins
from mussels is a labour intensive and cost ineffective* Correspondence: hjcha@postech.ac.kr
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unless otherwise stated.process, mass-production of recombinant MAPs has been
intensively attempted for practical use of MAP [1,8-12].
Previously, recombinant hybrid type MAP fp-151, com-
posed of six repeats of type 1 protein (fp-1) decapeptide at
both N- and C-termini of type 5 protein (fp-5), was suc-
cessfully designed and obtained in Escherichia coli system
with high production and purification yields [13].
Even though the establishment of recombinant fp-151
production has overcome the limitation in quantity, this
system still requires much improvement on its purity and
safety perspectives due to the undesirable impurities caused
by Gram-negative bacterium E. coli during cell disruption
and protein purification process. Due to adhesive nature
and positive polarity, purification of recombinant MAPs at
high purity suitable for in vivo applications has been a
difficult task. Formally, recombinant fp-151 expressed ind. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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method from surfactant Triton X-100-treated inclusion
body [13]. However, this method cannot fully remove im-
purities that MAP purified in this manner does not show
satisfactory purity nor safety in vivo situations. In addition,
those impurities are considered to contain large amount of
lipopolysaccharides (LPS) which are macro molecules con-
sisting of a lipid and a polysaccharide linked by a covalent
bond and are found in the outer membrane of Gram-
negative bacteria. LPS causes serious endotoxin-related im-
mune response problems in higher living organisms, such
as fever, shock and even death [14-16]. Thus, developing an
effective and reliable purification process to ensure high
purity and biological safety of recombinant MAP became
an important assignment to exploit it for practical in vivo
biomedical applications.
In the present work, a high resolution purification
process was proposed to enhance purity and ensure bio-
logical safety of E. coli-derived recombinant fp-151. This
purification process was composed of three strategies
targeting different steps of protein recovery: 1) multiva-
lent ion and chelating agent treatment of whole cells toFigure 1 Schematic representation of high resolution purification pro
Gram-negative E. coli.reduce cell membrane components, 2) non-ionic surfac-
tant washing of isolated inclusion body to reduce un-
desirable contaminants, and 3) final ion exchange
chromatographic recovery. The efficacy of this purifica-
tion process was assessed in many aspects of purity and
safety using various analyses including protein quantifi-
cation, endotoxin assay, and in vitro macrophage cell
tests.Results and discussions
We designed a purification process composed of three stra-
tegic steps in series to satisfy purity and biological safety of
recombinant MAP fp-151 for potential use in in vivo exper-
iments through the effective removing of impurities such as
contaminated proteins and LPS; 1) inclusion body isolation
after disruption of CaCl2/ethylenediaminetetraacetic acid
(EDTA)-treated harvested cells, 2) acetic acid extraction
after double washing of isolated inclusion body with Triton
X-114, and 3) ion exchange chromatography of acid-
extracted supernatant (Figure 1). The purity and endotoxin
levels of purified recombinant MAP were taken intocess for cytoplasmic expressed recombinant MAP in
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they are the most important safety parameters.
High resolution purification of recombinant MAP
There are many strategies to improve purity and safety
that are applicable for protein purification [17,18]. In the
case of bacterial cytoplasmic expression system such as
Gram-negative bacterium E. coli, cell membrane should
be disrupted to obtain target heterologous proteins. As
cell membrane is shattered during cell lysis, a lot of un-
desirable molecules such as proteins, lipids, and carbo-
hydrates are released into cell lysate. The main source of
impurities during protein purification is LPS which is
found in the outer membrane of gram-negative bacteria
and constitutes a large portion of cell membrane con-
tents [14]. Thus, effectively removing LPS for E. coli sys-
tem is thought as a key to ensure the purity and safety
of a final product [16,18-23]. Our previous MAP purifi-
cation method was based on simple acetic acid extrac-
tion after single Triton X-100 washing of isolated
inclusion body [13]. Thus, purity and biosafety of puri-
fied MAP were not guaranteed for in vivo standards. Be-
cause adhesive and positively charged nature of MAPs,
they have high chance to interact with many types of im-
purities, especially negatively charged cell components
such as LPS.
To remove cell membrane components from protein
solutions, differential centrifugation technique, such as
sucrose gradient centrifugation, is commonly used [24].
However, this is not suitable for the large-scale purifica-
tion because it is a very time consuming method that
requires more than 10–20 h of ultracentrifugation. An-
other interesting method is membrane washing with
multivalent ions such as CaCl2 and chelating agents such
as EDTA, which directly treats living cells to clean up
cell membrane components [25-27]. This method is
quite simple and fast compared to sucrose gradient cen-
trifugation. Thus, it is considered to be suitable for
large-scale purification of recombinant MAP. Another
big source of impurities resides in the inclusion body
which contains some unwanted or misfolded proteins as
well as the desired protein. Moreover, inclusion body is
inevitably contaminated by LPS after cell lysis, so inclu-
sion body should be also cleaned up efficiently. For
inclusion body washing, non-ionic surfactants are com-
mon choices because they are strong enough to separate
proteins while weak enough not to harm the protein
structure [28]. Especially, Triton X-100 and Triton X-
114 are popular non-ionic surfactants known for effect-
ively separating LPS from proteins [23,28-30].
As pre-treatment of harvested whole cells, CaCl2/EDTA
washing was used to remove LPS from the cell wall so that
the chance of LPS contamination for MAP during the cell
lysis can be reduced (Figure 1). After the cell pre-treatment,somewhat LPS-reduced cells were prepared for cell disrup-
tion. Then, non-ionic surfactant treatment was performed
for washing the isolated inclusion body containing recom-
binant MAP (Figure 1). For the surfactant washing, Triton
X-100 and Triton X-114 were assessed in combination to
establish the best performing condition against LPS. So-
dium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) analysis showed that recombinant MAP was
properly recovered at each step of purification as a major
band that appeared at ~23 kDa (Figure 2A). After adjusting
the concentration of recombinant MAP from each purifica-
tion step, endotoxin levels at each step were assessed
through limulus amoebocyte lysate (LAL) assay (Figure 2B).
We found that CaCl2/EDTA treatment reduced endotoxin
level of MAP below 1/4 value of crude whole cell lysate
(Figure 2B and Table 1). This result strongly suggests that
multivalent calcium ions attach to negatively charged LPS
residues on the cell membrane and then, EDTA chelation
on those calcium ions effectively removes LPS [25-27].
During the protein recovery step through acetic acid
extraction of inclusion bodies washed with non-ionic
surfactant (Figure 1), the sample washed twice with Tri-
ton X-114 presented the best performance in endotoxin
removal among four combinations of Triton X series
(inner plot in Figure 2B). Even though Triton X-100 and
Triton X-114 are sister chemicals, Triton X-114 has
shorter hydrophilic arm than Triton X-100 has; because
Triton X-114 has lower hydrophilic-lipophilic balance, it
has advantage over Triton X-100 when interacting with
heavy lipid chain of LPS [22,23]. Overall, cell pre-
treatment using CaCl2/EDTA and inclusion body wash-
ing with Triton X-114 greatly contributed to reduction
of LPS contents in the recombinant MAP along the
purification process.
To prepare highly pure and safety secured final
protein product, chromatography is a necessary purifi-
cation method. Several types of preparative chromatog-
raphy techniques, such as size-exclusion, affinity, and
ion exchange, can provide separation of mixtures.
Because MAP has high isoelectric point (pI) value
about 10 [13], cation exchanger, which has anionic
charged group, was used to filter out anionic impurities
(Figure 1). We found that protein impurities (P1 of
Figure 3A & B) were efficiently removed by salt gradi-
ent and the highly cationic MAP was eluted at the last
peak (P2 of Figure 3A & B) with greatly improved pur-
ity. Several small bands below the main MAP band
were considered as degraded forms which are likely to
possess similar positive charges with MAP (P2 of
Figure 3B). Because the recombinant MAP fp-151 used
in this work has highly repetitive sequence [13], the net
charge and hydrophobicity of degraded forms would
not be different much from MAP. In addition, because
negatively charged LPS were also filtered out by cation
Figure 2 (A) SDS-PAGE analysis and (B) endotoxin level determination of recombinant MAP samples according to each purification
step before ion exchange chromatography. The data represent mean +/− standard deviation and were analyzed 2-tails student t-test
(*p < 0.05, **p < 0.01, ***p < 0.005). Abbreviations: MW, molecular weight marker; WC, whole cells; IB, isolated inclusion body containing MAP after
disruption of CaCl2/EDTA-treated whole cells; X-100/100, acetic acid-extracted MAP after inclusion body washing with Triton X-100 twice; X-100/
114, acetic acid-extracted MAP after inclusion body washing with Triton X-100 and Triton X-114 in order; X-114/100, acetic acid-extracted MAP
after inclusion body washing with Triton X-114 and Triton X-100 in order; X-114/114, acetic acid-extracted MAP after inclusion body washing with
Triton X-114 twice.
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further reduced to nearly 20 EU per 1 mg total protein,
which was significantly low value compared to MAP
purified by previous method [13] and even to extracted
MAP from Triton X-114-washed inclusion body (Figure 3C
and Table 1).
Assessment of purity of recombinant MAP
Just as reducing endotoxin level to secure safety, im-
proving purity is another purpose of this purification
process. A purity of recombinant MAP was explored
with total carbohydrate/lipid amount determinationand high performance liquid chromatography (HPLC)
analysis. The total carbohydrate/lipid amount deter-
mination is meaningful because it can reveal the
amount of cellular components from E. coli left in
MAP after purification step. We found that cell pre-
treatment with CaCl2/EDTA cut the total quantities of
carbohydrates and lipids to about 1/6 and 1/11 of
whole cell lysate, respectively (Figure 4A). In addition,
the quantities of carbohydrates and lipids dropped
below 1 μg per 1 mg total protein through washing
twice with Triton X-114. Thus, these two strategic
treatments were proven to be useful in improving the
Table 1 Yield, endotoxin level, and purity of recombinant MAP in each purification step
Step Whole
cells
Inclusion body isolation after
disruption of CaCl2/
EDTA-treated cells
Acetic acid extraction after
Triton X-114 double




Total weight (mg) 25,500.00 9,600.00 516.00 275.47
Production yield (μg/mL) 7,697.80 7,309.75 2,956.25 1,578.21
Relative production yield (%) 100.00 94.96 38.40 20.50
Endotoxin level (EU/mg-total protein) 108,332.01 6,324.79 403.45 22.33
Relative endotoxin level (%) 100.00 5.84 0.37 0.02
Purity (%) - 35.30a) 89.81b) 99.90b)
a)calculation based on SDS-PAGE analysis.
b)calculation based on HPLC analysis.
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of total carbohydrates and lipids, not just in gaining the
safety.
Next, to check protein purity, both MAP samples be-
fore (washed twice with Triton X-114) and after being
purified by ion exchange chromatography were under-
gone HPLC analysis. While the sample washed twice
with Triton X-114 produced a chromatogram which
had one major peak and two minor peaks (Figure 4B-a),
where those two minor peaks correspond to the impur-
ities (Figure 3B, P1), the major portion from ion
exchange chromatography (Figure 3B, P2) demon-
strated only one major peak in HPLC chromatogram
(Figure 4B-b). This implies that the degraded forms of
MAP (minor bands in Figure 3B, P2), which have virtu-
ally the similar hydrophobicity, are eluted at the same
point. The purity of recombinant MAP sample after be-
ing purified by ion exchange chromatography was sig-
nificantly increased to 99.9% compared to that (89.8%)
of the sample only after acid extraction of Triton X-
114-treated inclusion body (Table 1). Consequently, the
results of HPLC analyses indicate that ion exchange
chromatography step eliminated undesired proteins ef-
ficiently and improved the purity of recombinant MAP
dramatically. Interestingly, this HPLC results can also
explain what those minor bands shown together with
MAP in P2 of Figure 3B are; because those minor
bands were not separately shown on HPLC chromato-
gram (Figure 4B-b), they can be considered as degraded
forms of MAP, which has similar hydrophobicity that
they appear at the same elution point with MAP.
Assessment of biological safety of purified recombinant
MAP
Even though most of the impurities were dramatically
reduced by the proposed purification process, purified
recombinant MAP should meet the biological safety pa-
rameters, such as inflammation, viability, cytotoxicity,
and apoptosis, for in vivo applications. Residual impur-
ities, especially LPS, can cause the innate immune re-
sponse that expressions of pro-inflammatory cytokines,such as tumour necrosis factor-alpha (TNF-α) and
interleukin-6 (IL-6), were assessed using RAW 264.7
macrophage cell line. The expression levels of TNF-α
and IL-6 were notably decreased along purification
steps and presented lower cytokine expressions than 1
EU LPS standard-treated sample, whereas high levels of
TNF-α and IL-6 were observed in recombinant MAP
purified by the previous method which was based on
simple acetic acid extraction after single Triton X-100
washing of isolated inclusion body [13] (Figure 5).
These low activations of inflammatory signal transduc-
tion in macrophage cells were ascribed to efficacy of
CaCl2/EDTA treatment and Triton X-114 washing in
LPS reduction. Furthermore, almost no inflammatory
cytokines were expressed by final recombinant MAP
sample after ion exchange chromatography (Figure 5).
This result indicates that the final product of this puri-
fication process can be applied to in vivo applications
without inflammatory response. In addition, other cri-
teria of cellular responses, such as viability, cytotoxicity,
and apoptosis, were assessed using macrophage cells to
ensure further biosafety of purified recombinant MAP.
As results, MAP purified by our purification process
showed high viability, low cytotoxicity, and low apop-
totic activity compared to positive controls (Figure 6).
Taken together, our highly purified recombinant MAP
can be successfully used as a safe adhesive biomaterial
for in vivo applications without triggering cytotoxicity
and inflammatory response.
Conclusions
Here, the establishment of purification process for
Gram-negative E. coli-derived recombinant MAP, com-
posed of inclusion body isolation after disruption of
multivalent ion CaCl2/chelating agent EDTA-treated
cells, acetic acid extraction after inclusion body wash-
ing twice with non-ionic surfactant Triton X-114, and
ion exchange chromatography purification of acid-
extracted solution with cation exchanger, was achieved
to secure high purity and biological safety standards.
The purity and safety parameters were confirmed by
Figure 3 (A) Ion exchange chromatogram, (B) SDS-PAGE analysis, and (C) endotoxin level determination of recombinant MAP sample
after ion exchange chromatography purification. The data represent mean +/− standard deviation and were analyzed 2-tails student t-test
(*p < 0.05, **p < 0.01, ***p < 0.005). Abbreviations: MW, molecular weight marker; WC, whole cells; X-114/114, acetic acid-extracted MAP after
inclusion body washing with Triton X-114 twice; P1, first peak fraction from cation exchanger of acetic acid-extracted solution after inclusion body
washing with Triton X-114 twice; P2, second peak fraction from cation exchanger of acetic acid-extracted solution after inclusion body washing
with Triton X-114 twice; ppMAP, purified MAP based on previous method.
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Figure 4 Assessment of purity of recombinant MAP. (A) Total carbohydrate/lipid amount determination and (B) HPLC chromatograms for
protein purity determination. The data represent mean +/− standard deviation and were analyzed 2-tails student t-test (*p < 0.05, **p < 0.01, ***p < 0.005).
Abbreviations: WC, whole cells; IB, isolated inclusion body containing MAP after disruption of CaCl2/EDTA-treated whole cells; X-114/114,
acetic acid-extracted MAP after inclusion body washing with Triton X-114 twice. P2, second peak fraction from cation exchanger of acetic
acid-extracted solution after inclusion body washing with Triton X-114 twice.
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purification process. LAL assays revealed that the endo-
toxins were effectively eliminated; HPLC assay and total
carbohydrate-lipid amount determination presented
notably improved purity; various in vitro macrophage
cell tests on inflammatory response and cellularresponses such as cell viability, cytotoxicity, and apop-
tosis confirmed the biological safety of final purified
product. This highly purified recombinant MAP with
secured biological safety can be successfully used as a
promising bioadhesive for in vivo tissue engineering
and biomedical applications.
Figure 5 Assessment of biological safety of purified recombinant MAP using inflammatory response assays on RAW 264.7 macrophage
cells. (A) TNF-α and (B) IL-6 mRNA expressions were observed by treating MAP samples at each purification step. The data represent mean +/−
standard deviation and were analyzed 2-tails student t-test (*p < 0.05, **p < 0.01, ***p < 0.005). Abbreviations: NC, non-treated negative control;
WC, whole cells; IB, isolated inclusion body containing MAP after disruption of CaCl2/EDTA-treated whole cells; X-100/100, acetic acid-extracted
MAP after inclusion body washing with Triton X-100 twice; X-100/114, acetic acid-extracted MAP after inclusion body washing with Triton X-100
and Triton X-114 in order; X-114/100, acetic acid-extracted MAP after inclusion body washing with Triton X-114 and Triton X-100 in order; X-114/
114, acetic acid-extracted MAP after inclusion body washing with Triton X-114 twice; IE: MAP fraction through cation exchange chromatography
of acetic acid-extracted solution after inclusion body washing with Triton X-114 twice; ppMAP, purified MAP based on previous method; LPS 1EU,
LPS standard with 1 endotoxin unit; LPS 5EU, LPS standard with 5 endotoxin unit; LPS 10EU, LPS standard with 10 endotoxin unit.
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Expression of recombinant MAP in E. coli
Recombinant fp-151 was produced in E. coli as de-
scribed previously [13]. In brief, transformed E. coli
BL21 (DE3) cells were cultured in 5 L Luria-Bertani (LB)
medium supplemented with 50 μg/mL ampicillin
(Sigma, St. Louis, MO, USA) using a 10 L bioreactor
(KoBiotech, Incheon, Korea) at 37°C and 300 rpm. At
optical density 600 nm (OD600) of 0.4–0.6, 1 mM
isopropyl-β-D-thiogalactopyranoside (IPTG; Sigma) was
added to the broth to induce protein expression, and
further cultured for 8 h at 37°C and 300 rpm. After har-
vesting by centrifugation (Hanil Science Industrial,Incheon, Korea) of culture broth at 9,000 × g for 10 min
at 4°C, cell pellets were stored at −80°C for further
analysis.
Inclusion body isolation after disruption of CaCl2/
EDTA-treated whole cells
Harvested cell pellets containing recombinant fp-151
were washed (resuspended and pelleted) with 15 mL of
each washing solution per gram wet weight, in order of
100 mM Tris–HCl (pH 8.0), 5 mM CaCl2 in 100 mM
Tris–HCl (pH 8.0), and 10 mM EDTA (Sigma) in
100 mM Tris–HCl (pH 8.0). This washing procedure
was repeated three times. In the final cycle of washing
Figure 6 (See legend on next page.)
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Figure 6 Assessment of biological safety of purified recombinant MAP using cellular response assays on RAW 264.7 macrophage cells.
(A) Cell viability, (B) cytotoxicity, and (C) apoptotic cell death were observed by treating MAP samples at each purification step. The data
represent mean +/− standard deviation and were analyzed 2-tails student t-test (*p < 0.05, **p < 0.01, ***p < 0.005). Abbreviations: NC, non-treated
negative control; WC, whole cells; IB, isolated inclusion body containing MAP after disruption of CaCl2/EDTA-treated whole cells; X-114/114, acetic
acid-extracted MAP after inclusion body washing with Triton X-114 twice; IE: MAP fraction through cation exchange chromatography of acetic
acid-extracted solution; ppMAP, purified MAP based on previous method; LPS 1EU, LPS standard with 1 endotoxin unit; LPS 10EU, LPS standard
with 10 endotoxin unit.
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(10 mM Tris–HCl and 100 mM sodium phosphate;
pH 8.0) per gram wet weight. Cells were lysed with con-
stant cell-disruption system (Constant Systems, North-
ants, England) at 20 kpsi. Cell lysates were centrifuged at
9,000 × g for 20 min at 4°C, and cell debris harbouring
inclusion body was collected.Acetic acid extraction after Triton X-114 double washing
of inclusion body
The isolated inclusion body was treated with Triton X-
114 washing twice. It was suspended in Triton X-114
washing buffer (1% (v/v) Triton X-114 (Sigma), 1 mM
EDTA, and 50 mM Tris–HCl; pH 8.0) with 10 mmol
phenylmethanesulfonyl fluoride (PMSF; Sigma) and
1 mg/mL lysozyme (Bio Basic Canada Inc., Ontario,
Canada), and agitated overnight. After centrifugation, in-
clusion bodies were resuspended in Triton X-114 wash-
ing buffer to remove PMSF and lysozyme. The isolated
inclusion bodies were resuspended in 40 mL of 25% (v/
v) acetic acid per gram wet weight to specifically extract
recombinant fp-151. The extracted solution was centri-
fuged at 9,000 × g for 20 min at 4°C, and the supernatant
was collected, dialyzed in distilled water (DW) with 0.1%
(v/v) acetic acid, and freeze-dried.Ion exchange chromatography purification
For further purification of recombinant fp-151, fast protein
liquid chromatography (FPLC; GE Healthcare, Bucking-
hamshire, UK) system was used. Sample was prepared by
dissolving freeze-dried acid-extracted recombinant fp-151
in binding buffer (20 mM sodium acetate; pH 4.0). Then,
cationic exchange column (HiTrap SP XL; GE Healthcare)
was used for separating fp-151 and impurities through lin-
ear gradient of elution buffer (20 mM sodium acetate and
2 M NaCl; pH 4.0) with flow rate of 1 mL/min.Total protein quantification and SDS-PAGE analysis
Protein recovery of sample at each purification step was
quantified by Bradford assay (Bio-Rad, Hercules, CA,
USA) and 12% (w/v) SDS-PAGE. Band intensity on
SDS-PAGE was analyzed by Gel-Pro Analyzer (Media
Cybernetics, Rockville, MD, USA).LAL assay for endotoxin level determination
After setting the sample quantification to 1 mg/mL,
endotoxin levels were determined using the Pierce® LAL
Chromogenic Endotoxin Quantitation Kit (Thermo Sci-
entific, Waltham, Massachusetts, USA), which is a quan-
titative endpoint assay for detection of Gram-negative
bacterial endotoxins. The activation of a pro-enzyme in
the modified LAL is catalyzed by bacterial endotoxin. A
total 50 μL of LAL solution was added to each well of
50 μL sample or standard, and the plates were further
incubated for 10 min at 37°C. Then, 100 μL substrate
solution was added with 6 min incubation at 37°C
followed by addition of 50 μL of 25% (v/v) acetic acid
to stop reaction. The absorbance was measured at
410 nm using a microplate absorbance spectrophotometer
(Bio-Rad).
Total carbohydrate and lipid amount determination
The phenol-sulfuric acid assay was performed to deter-
mine the total quantity of carbohydrates in the samples
at each purification step. All samples were freeze-dried
and ten milligram of each sample was dissolved in
500 μL of 4% (w/v) phenol (Sigma) and 2.5 mL of 96%
(v/v) sulfuric acid (Sigma). 1 mg/mL glucose was used in
5–50 μL of DW for the standard curve, and the optical
density was measured at 490 nm. The total quantity of
lipids in the samples at each step was analyzed by the
sulfo-phospho vanillin colorimetric method. 10 mg of
each sample (freeze-dried) was dissolved in chloroform.
For the standard curve, 10–100 μg triolein were used.
After drying of the chloroform, 100 μL DW was added.
The samples were mixed with 2 mL of 96% (v/v) sulfuric
acid, boiled for 10 min in a water bath and cooled for
5 min. The phosphoric acid-vanillin reagent was pre-
pared with 85% (v/v) phosphoric acid (Sigma) and 1.2 g/
L vanillin (Sigma). After treatment of 5 mL phosphoric
acid-vanillin reagent, the samples were warmed at 37°C
for 15 min and cooled for 10 min. After the reaction, the
value of optical density was measured at 530 nm.
HPLC analysis for protein purity determination
Recombinant fp-151 samples collected before and after
ion exchange chromatography were analyzed by HPLC
(Gilson, Middleton, WI, USA) with reverse phase
Hypersil™ BDS 3 μm C18 column (4.6 × 100 mm;
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ear gradient of acetonitrile (0–100%, v/v) and HPLC
grade water with 0.1% trifluoroacetic acid, and moni-
tored by a UV detector at 280 nm.
In vitro macrophage cell assays
To check inflammatory response of purified recombin-
ant fp-151, expressions of inflammatory cytokines such
as TNF-α and IL-6 were measured after treatment of the
samples at each purification step on RAW 264.7 mouse
macrophage cells. Total 3 × 104 cells were seeded onto
96-well plate and incubated in Dulbecco’s modified Es-
sential Medium (DMEM; Hyclone, Logan, UT, USA)
supplemented with 10% (v/v) fetal bovine serum
(Hyclone) and penicillin (100 unit/mL; Hyclone)/strepto-
mycin (100 μg/mL; Hyclone) at 37°C under 5% CO2
humid atmosphere. After change of culture media, 4 μg
MAP sample was added to the cells in a well and the se-
cretion of inflammatory cytokines was analysed. Detection
of expressed TNF-α and IL-6 in culture media was per-
formed with sandwich enzyme-linked immunosorbent
assay (ELISA). Capture and detection antibodies for TNF-α
and IL-6 and standard recombinant mouse TNF-α and
IL-6 were purchased from R&D Systems (Minneapolis,
USA). All procedures were following manufacturer’s
protocol.
Cell viability, cytotoxicity, and apoptosis were also
examined using RAW 264.7 mouse macrophage cells.
Total 2 × 104 cells were plated onto 96-well plate and
sample treatment was the same than the inflammation
assay. Measurements of viability, cytotoxicity, and apop-
tosis of the cells were performed by ApoTox-Glo™ Trip-
lex Assay (Promega, Madison, WI, USA) as following
manufacturer’s protocol.
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